Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Myrin 2 · 1 trial · 1 indication
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | Test |
| B | ACTIVE_COMPARATOR | Reference |
| Name | Type | Description |
|---|---|---|
| Myrin© 2 (Rifampicin + Isoniazid) | DRUG | Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg |
| Rimactane® (Rifampicin) | DRUG | One (1) capsule of Rifampicin 300 mg |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years, inclusive. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). * An informed consent document signed and dated by the subject. * Subjects willing and able to comply with scheduled ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Viatris, Inc. | VTRS | 1 | PHASE3 | Bedaquiline |
| Johnson & Johnson | JNJ | 1 | PHASE2 | Bedaquiline, Background Regimen |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT164a1, BNT164b1 |
Myrin 2 is a small molecule being developed by Pfizer, Inc. for the treatment of tuberculosis. It is currently in Phase 1 clinical development as an investigational drug. The drug is being studied in the infectious disease therapeutic area.
Myrin 2 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical research on this investigational small molecule for tuberculosis.
Myrin 2 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for the treatment of tuberculosis.
Myrin 2 has one completed Phase 1 clinical trial, identified as NCT01311505. This was a bioequivalence study comparing a fixed-dose combination of rifampicin and isoniazid (Myrin 2) against the reference drug rifampicin (Rimactane). The trial enrolled 21 healthy male volunteers in the Philippines.
Yes, Myrin 2 is a fixed-dose combination containing rifampicin and isoniazid. It was studied in a bioequivalence trial comparing it to the reference drug rifampicin (Rimactane) to assess how the combination performs relative to the single reference drug.